Downloading...
Download

SGEN

PIRS Pieris Pharmaceuticals Huge Upside Potential Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS): AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and 1.2Bil potential milestone payments Servier 40Mil upfront payment and 447Mil potential milestone payments inhaled program PRS-220 for the treatment of IPF. selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis On 8/16/2021 Morgan Stanley reported 1,675,969 shares of PIRS for $6.42Mil, an increase of +104.6% for an ownership of 2.512% in the company On 4/26/2021 HC Wainwright brokerage Reiterated Rating to Buy and a price target of $9.00 On 6/30/2021 Jefferies Financial Group brokerage Boosted Price Target to Buy from $6.00 to $8.00 Usually i have price targets lower than most analysts, but on PIRS, my price target is 10usd. I`m looking forward to read your opinion about it.
PLong
by TopgOptions
4
SGENSGEN Part 3 Listen to all three parts ( twice ). Try to replicate some of the lines. I am 100% certain that you will miss parts of it. Don't worry, and expect even the simplest thing, drawing arrange box, is different for me than it is for you when your first doing this. Don't worry. Even a simple range box may take you a couple weeks to get familiar and more comfortable with your decisions, but as that improves and you feel comfortable, you may have to do a little bit more work on fib extensions. Don't worry, except this, but do it. I'm showing you how to use your brain to focus on the market with more objectivity, and when you're able to focus on the market you may have uncomfortable feelings, but now it will be more specifically related to your understanding and work on the price dynamics of the market you are evaluating, and not on your underlying fears and stress that have nothing to do with the market.If you have fears and stress related to remorse, unrealistic impulses, and many other causes, it would obviously be better to talk with a professional who understands markets and fear related issues when trading markets, but I cannot offer that to you now, and that's not the business that I'm in... which is to make money with my own account. Underlying issues regarding stress and fear and other emotions emanate from previous experiences in your life that have nothing to do with trading, and a PhD level coach would claim that these emotions are so ingrained in your behavior... that they even prevent you from developing a trading plan, and then trading your plan... and this is because when the market becomes threatening in that it might have a significant drawdown, or you are actually profitable in a trade, but it hasn't reached your target and now it's correcting $1000 in your stressing out about this even though your plan was to have a stop in a target and it is still a good trait... if you can handle drawdowns on a profitable trade and it triggers a stress reaction and you actually start thinking about the drawdown, not the trade, you will break your plan. According to Andrew Menaker who I hired for 10 sessions, underlying fears and behavior related to stress are almost uncontrollable with traders that do not have a clear grasp of these problem issues for them. I can't be your Andrew Menaker, but at least I can focus you on the chart and the behaviors that I think are credible, repeatable behaviors of the market. It is my hope that you can manage at least some of your underlying issues regarding fear and other counterproductive feelings by focusing more on the chart, and I think you can do this if you actually focus more on the chart, and one way to do this is to record yourself and try to tell the story and discover reasons based on the chart why the market is doing what it's doing and where you see the buyers and the sellers as well as the price action,and other behaviors that are are associated with the market.
SEducation
by ScottBogatin
1
Major Breakout In $SGEN$SGEN has been on a long-term bull run as we look at the weekly chart. Positive topline results signal that the bull run is set to continue and we expect $SGEN to keep racking up new 52-week highs. Seattle Genetics (NASDAQ:SGEN) is up in reaction to positive results from a Phase 2 clinical trial, HER2CLIMB, evaluating combination of tucatinib, Roche's Herceptin (trastuzumab) and chemo agent capecitabine compared to trastuzumab and capecitabine alone in patients with locally advanced unresectable/metastatic HER2-positive breast cancer. The study met the primary endpoint of progression-free survival (PFS) at month 48 with 48% less risk of cancer progression or death (hazard ratio = 0.54). Key secondary endpoints of overall survival (OS) and PFS in patients with brain metastases were also met. On the safety front, the most common adverse events were diarrhea, palmar-plantar erythrodysaesthesia syndrome (redness, swelling and pain in the palms and/or soles of the feet), nausea, fatigue and vomiting. Serious/life-threatening adverse events included diarrhea (12.9% vs 8.6% in the comparator arm), increased AST (4.5% vs. 0.5%), increased ALT (5.4% vs. 0.5%) and increased bilirubin (0.7% vs. 2.5%). Increases in AST, ALT and bilirubin indicate liver stress/damage. Based on the successful results, the company intends to unblind the trial and offer tucatinib, a tyrosine kinase inhibitor, to patients in the comparator arm. It also plans to file a U.S. marketing application in Q1 2020. As always, trade with caution and use protective stops. Good luck to all!
SLong
by OptionsGains